ABIONYX Pharma SA (GB:0RAG)
LSE:0RAG
0RAG Stock Chart & Stats
€3.55
€0.05(4.00%)
At close: 4:00 PM EST
€3.55
€0.05(4.00%)
Day’s Range― - ―
52-Week Range€1.16 - €5.29
Previous CloseN/A
Volume167.00
Average Volume (3M)1.33K
Market Cap
€127.52M
Enterprise Value€127.92M
Total Cash (Recent Filing)€3.52M
Total Debt (Recent Filing)€3.81M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding35,511,654
10 Day Avg. Volume331
30 Day Avg. Volume1,335
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€4.66M
Bulls Say, Bears Say
Bulls Say
Focused ApoA‑I Therapeutic PlatformABIONYX’s concentrated R&D on a recombinant apoA‑I platform creates a clear scientific focus and potential multi‑indication pipeline. A durable platform approach can leverage shared biology, reduce discovery risk per program, and support long‑term value if clinical proof emerges.
Positive (but Reduced) Equity BaseMaintaining positive equity provides an essential solvency buffer and preserves access to financing options compared with insolvent peers. Although equity has eroded, the present positive balance reduces immediate bankruptcy risk and supports continued R&D investment over the coming months.
Operating Cash Burn Showing ImprovementA reduction in operating cash outflows signals incremental progress in cost control or operational efficiency. If sustained, lower burn narrows near‑term financing needs, extends runway for clinical programs, and increases the chance management can reach clinical inflection points before raising capital.
Bears Say
Persistent Negative Cash FlowConsistent operating and free cash outflows create structural funding pressure that typically necessitates external financing or asset sales. Over months this raises dilution and refinancing risk, constrains discretionary R&D spending, and can force program prioritization or delays if new capital is costly or unavailable.
Severely Negative Margins And ProfitabilityDeeply negative gross and EBIT margins show the business is far from scalable profitability and sensitive to cost structure. Without clear revenue scale or substantial margin improvement, persistent losses will erode resources and weaken the sustainability of clinical programs over the medium term.
Rising Leverage And Eroded EquityIncreasing debt relative to a shrinking equity base reduces financial flexibility and raises the cost and risk of future funding. Higher leverage limits strategic options, increases fixed obligations, and heightens the chance that further losses force dilutive financing or reprioritization of R&D investment.
0RAG FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest share price was €1.16 and its highest was €5.29 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €127.52M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 24, 2026 which is in 167 days.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Mar 12, 2026. The company reported -€0.092 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.092.
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 35,511,654 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.053%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in GB:0RAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.